Compare ALEMBIC PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AUROBINDO PHARMA ALEMBIC PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 27.7 11.5 240.3% View Chart
P/BV x 2.8 1.4 197.9% View Chart
Dividend Yield % 1.9 0.8 253.7%  

Financials

 ALEMBIC PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-21
AUROBINDO PHARMA
Mar-21
ALEMBIC PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1501,023 112.4%   
Low Rs527333 158.1%   
Sales per share (Unadj.) Rs274.4422.8 64.9%  
Earnings per share (Unadj.) Rs56.792.0 61.7%  
Cash flow per share (Unadj.) Rs66.0110.0 60.1%  
Dividends per share (Unadj.) Rs14.004.00 350.0%  
Avg Dividend yield %1.70.6 283.1%  
Book value per share (Unadj.) Rs260.9374.3 69.7%  
Shares outstanding (eoy) m196.56585.94 33.5%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.11.6 190.5%   
Avg P/E ratio x14.87.4 200.5%  
P/CF ratio (eoy) x12.76.2 205.9%  
Price / Book Value ratio x3.21.8 177.4%  
Dividend payout %24.74.3 567.6%   
Avg Mkt Cap Rs m164,818397,398 41.5%   
No. of employees `000NANA-   
Total wages/salary Rs m10,51235,350 29.7%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m53,931247,746 21.8%  
Other income Rs m8753,809 23.0%   
Total revenues Rs m54,806251,555 21.8%   
Gross profit Rs m14,80181,480 18.2%  
Depreciation Rs m1,83510,554 17.4%   
Interest Rs m160745 21.5%   
Profit before tax Rs m13,68173,990 18.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,53320,098 12.6%   
Profit after tax Rs m11,14853,892 20.7%  
Gross profit margin %27.432.9 83.4%  
Effective tax rate %18.527.2 68.2%   
Net profit margin %20.721.8 95.0%  
BALANCE SHEET DATA
Current assets Rs m25,779198,235 13.0%   
Current liabilities Rs m12,808106,652 12.0%   
Net working cap to sales %24.137.0 65.1%  
Current ratio x2.01.9 108.3%  
Inventory Days Days2319 122.4%  
Debtors Days Days252 4.6%  
Net fixed assets Rs m41,311135,778 30.4%   
Share capital Rs m393586 67.1%   
"Free" reserves Rs m50,883218,713 23.3%   
Net worth Rs m51,276219,299 23.4%   
Long term debt Rs m1,9991,684 118.7%   
Total assets Rs m67,090334,013 20.1%  
Interest coverage x86.4100.3 86.1%   
Debt to equity ratio x00 507.7%  
Sales to assets ratio x0.80.7 108.4%   
Return on assets %16.916.4 103.0%  
Return on equity %21.724.6 88.5%  
Return on capital %26.033.8 76.8%  
Exports to sales %66.853.8 124.2%   
Imports to sales %12.716.4 77.4%   
Exports (fob) Rs m36,020133,248 27.0%   
Imports (cif) Rs m6,84540,615 16.9%   
Fx inflow Rs m36,020133,248 27.0%   
Fx outflow Rs m6,84544,946 15.2%   
Net fx Rs m29,17588,302 33.0%   
CASH FLOW
From Operations Rs m14,63433,289 44.0%  
From Investments Rs m-8,3885,987 -140.1%  
From Financial Activity Rs m-5,974-13,648 43.8%  
Net Cashflow Rs m26225,831 1.0%  

Share Holding

Indian Promoters % 69.1 48.8 141.7%  
Foreign collaborators % 0.5 3.1 16.6%  
Indian inst/Mut Fund % 17.8 38.3 46.4%  
FIIs % 6.0 20.8 28.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 48.2 63.1%  
Shareholders   106,437 338,639 31.4%  
Pledged promoter(s) holding % 0.0 14.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SUN PHARMA    CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    

Yellow Ad

Advertisement

A One Stock Gift in 1990 Turns into Rs 130 Crores

In 2017, Ravi made headlines by calling a leading business news channel with a surprising announcement - his grandfather had left him 20,000 shares of only one stock.

And on the day of his call - these shares were worth Rs 130 crore.

Can you guess which is this company?

It's MRF.

Ravi's story is one of the amazing stories of becoming Crorepati from a single stock.

But the question is, how to find that one stock with crorepati potential?

To find the answer to this million-dollar question, join our 'One Stock Crorepati' MEGA summit on 30th June, where we will reveal details of what we call a potential 'crorepati' stock...

Learn more



Today's Market

Sensex Zooms 462 Points, Nifty Ends Near 15,700; Auto & FMCG Stocks Rally(Closing)

Indian share markets ended the week on a firm note tracking positive global cues.

Related Views on News

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling(Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover?(Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jun 24, 2022 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - SANDU PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS